<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(28)</volume><submitter>Gong L</submitter><pubmed_abstract>Yindanxinnaotong capsule (YDXNT), a traditional Chinese formula, has been used to treat cardio-cerebrovascular diseases for several decades. Previous research has focused on evaluating the pharmacological properties and main compounds of YDXNT &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i>. However, the multiple bioactive compounds &lt;i>in vivo&lt;/i> remain poorly understood. In the present research, an integrative strategy using UPLC-Q-TOF-MS combined with UPLC-QqQ-MS was employed to detect the absorbed constituents and investigate the pharmacokinetics of main compounds in the plasma after oral administration of YDXNT. UPLC-Q-TOF-MS was developed to detect the absorbed constituents and their metabolites in the plasma after oral administration in rats. A total of 52 constituents, including 44 prototype co</pubmed_abstract><journal>RSC advances</journal><pagination>15725-15739</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9080097</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Identification of absorbed constituents and evaluation of the pharmacokinetics of main compounds after oral administration of yindanxinnaotong by UPLC-Q-TOF-MS and UPLC-QqQ-MS.</pubmed_title><pmcid>PMC9080097</pmcid><pubmed_authors>Yang H</pubmed_authors><pubmed_authors>Yin X</pubmed_authors><pubmed_authors>Fan M</pubmed_authors><pubmed_authors>Ma X</pubmed_authors><pubmed_authors>Cheng L</pubmed_authors><pubmed_authors>Gong L</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Yuan H</pubmed_authors><pubmed_authors>Wang L</pubmed_authors><pubmed_authors>Liang R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identification of absorbed constituents and evaluation of the pharmacokinetics of main compounds after oral administration of yindanxinnaotong by UPLC-Q-TOF-MS and UPLC-QqQ-MS.</name><description>Yindanxinnaotong capsule (YDXNT), a traditional Chinese formula, has been used to treat cardio-cerebrovascular diseases for several decades. Previous research has focused on evaluating the pharmacological properties and main compounds of YDXNT &lt;i>in vitro&lt;/i> and &lt;i>in vivo&lt;/i>. However, the multiple bioactive compounds &lt;i>in vivo&lt;/i> remain poorly understood. In the present research, an integrative strategy using UPLC-Q-TOF-MS combined with UPLC-QqQ-MS was employed to detect the absorbed constituents and investigate the pharmacokinetics of main compounds in the plasma after oral administration of YDXNT. UPLC-Q-TOF-MS was developed to detect the absorbed constituents and their metabolites in the plasma after oral administration in rats. A total of 52 constituents, including 44 prototype co</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Apr</publication><modification>2025-04-26T15:23:44.049Z</modification><creation>2025-02-19T03:24:45.574Z</creation></dates><accession>S-EPMC9080097</accession><cross_references><pubmed>35539456</pubmed><doi>10.1039/c7ra12659j</doi></cross_references></HashMap>